MAP2K7 and cancer: A further reason to combine BRAF and MEK inhibitors in patients is to decrease the development of secondary RAS-driven cancers, such as squamous cell carcinomas [43] and chronic lymphoblastic leukemia [44], that have been reported in patients inhibitor treated with BRAF monotherapy.